ArticleNature communications2023
ADRA2A and IRX1 are putative risk genes for Raynaud's phenomenon.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Novel pleiotropic loci link vascular and immune pathways in systemic sclerosis and primary Raynaud's phenomenon.Rheumatology (Oxford, England) · 2026Pooled it
- An epidemiological study estimating the burden of cancer risk in patients with Raynaud's phenomenon.Clinical rheumatology · 2026Article
- Obesity due to MC4R deficiency is associated with reduced cholesterol, triglycerides and cardiovascular disease risk.Nature medicine · 2025Article
- Pediatric erythromelalgia from multidisciplinary perspectives: a scoping review.Pediatric research · 2025Article
- Integrative exome sequencing and machine learning identify MICB and interferon pathway genes as contributors to SSc risk.Annals of the rheumatic diseases · 2025Article
- Cold responses and hormonal echoes: a comprehensive view of Raynaud's vascular dysfunction.Inflammopharmacology · 2025Review
- α2 adrenoceptors, cold-induced vasoconstriction, and Raynaud's phenomenon.Cell genomics · 2025Article
- Response to Dr. Nicholas A. Flavahan's and Dr. Ali H. Eid's letters regarding our recent publication in Cell Genomics.Cell genomics · 2025Article
- Genetic and functional analysis of Raynaud's syndrome implicates loci in vasculature and immunity.Cell genomics · 2024Article
- Raynaud's Phenomenon: A Current Update on Pathogenesis, Diagnostic Workup, and Treatment.Vascular specialist international · 2024Review
- Raynaud phenomenon: from GWAS to drug repurposing.Nature reviews. Rheumatology · 2024Article
- Inhibiting Intracellular αInternational journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 3 countries.
Funding
Abstract
Raynaud's phenomenon (RP) is a common vasospastic disorder that causes severe pain and ulcers, but despite its high reported heritability, no causal genes have been robustly identified. We conducted a genome-wide association study including 5,147 RP cases and 439,294 controls, based on diagnoses from electronic health records, and identified three unreported genomic regions associated with the risk of RP (p < 5 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.